Alto Neuroscience (ANRO) Change in Receivables (2023 - 2024)
Alto Neuroscience's (ANRO) quarterly Change in Receivables came in at -$8000.0 in Q1 2024, down 121.62% year-on-year from $37000.0 in Q2 2023, and up 97.29% quarter-over-quarter from -$295000.0 in Q3 2023.
Alto Neuroscience (ANRO) Change in Receivables (2023 - 2024) Analysis & Trends
Alto Neuroscience has disclosed Change in Receivables across 2 years of filings, most recently posting -$8000.0 for Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Mar 31, 2023 | 37,000.00 |